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Abstract: Activity-directed synthesis (ADS) is a structure-blind, 
functional-driven molecular discovery approach. In this Concept, four 
case studies highlight the general applicability of ADS and showcase 
its flexibility to support different medicinal chemistry strategies. ADS 
deliberately harnesses reactions with multiple possible outcomes, and 
allows many chemotypes to be evaluated in parallel. Resources are 
focused on bioactive molecules which emerge in tandem with 
associated synthetic routes. Some of the future challenges for ADS 
are highlighted, including the realisation of an autonomous molecular 
discovery platform.  The prospects for ADS to become a mainstream 
lead generation approach are discussed. 
Introduction 
The discovery of bioactive small molecules is an enduring 
challenge in both medicinal chemistry and chemical biology.  Lead 
generation is generally driven by iterative cycles in which series 
of molecules are designed, synthesised, purified and tested.[1]  
Established lead generation approaches tend be both time- and 
resource-intensive, in part because a similar investment is made 
in all molecules, irrespective of their ultimate biological activity.  
Although automation is widely harnessed within the individual 
stages of discovery workflows,[2] it is rare for adjacent stages to 
be integrated, and for all activities (particularly purification) to be 
performed in parallel and with matched throughput.  Moreover, a 
limited reaction toolkit dominates molecular discovery,[3] which 
has led to an uneven exploration of chemical space and has 
tended to focus attention on molecules with sub-optimal 
properties.[4]  Molecular design hypotheses are typically 
investigated one-by-one, focusing on individual series of closely-
related molecules that may be prepared using a specific reaction 
drawn from the standard toolkit.  How, then, might diverse 
chemical space be explored more efficiently to drive the discovery 
of both drugs and chemical probes? 
Activity-directed synthesis (ADS) is a structure-blind, function-
driven approach in which active compounds emerge in parallel 
with an associated synthetic route. The approach borrows 
concepts from the evolution of biosynthetic pathways to natural 
products, a process that is driven by functional benefit to the host 
organism.[5] A conceptually related approach termed “synthetic 
fermentation” also identifies compounds based on their biological 
activity, and enables the discovery of bioactive -peptides.[6,7] In 
ADS, reactions that have the potential to yield multiple possible 
products are deliberately exploited.  Arrays of reactions are 
performed on a microscale (typically ~10 mol), and the resulting 
crude product mixtures are directly screened for biological 
function. A crucial step is to show that none of the individual 
components display activity in the screening assay.  The reaction 
arrays may be assembled from stock solutions of components 
(e.g. substrates, co-substrates, catalysts, solvents), typically 
using multi-channel pipettes, via processes that are amenable to 
automation.  After minimal work-up, such as scavenging to 
remove metals, the crude product mixtures are diluted and 
screened for biological function.  Here, as multiple products may 
be formed, screening is performed at a specific total concentration 
of the products formed from the limiting substrate.  Hit reactions 
that yield bioactive products are thereby identified and can inform 
the design of subsequent reaction arrays.  In subsequent rounds 
of ADS, screening may be performed at lower total product 
concentration in order to drive the emergence of reactions that 
yield more active product mixtures.  Finally, the hit reactions are 
scaled up, and the responsible bioactive products are purified, 
structurally elucidated and characterised. 
To allow exploration of diverse chemical space via ADS, it is 
important to harness reactions that have multiple (and diverse) 
possible outcomes.  Here, the selection of underpinning chemistry 
contrasts starkly with that for conventional discovery workflows in 
which reactions that yield specific, designed molecules are 
preferred.  Metal-carbenoid chemistry has many of attributes that 
are required to underpin ADS.[8]  First, the diazo substrates can 
undergo many different types of reaction (e.g. O-H, N-H and C-H 
insertion; cyclopropanation; ylid formation) in either an inter- or an 
intramolecular sense.  Second, the distribution of alternative 
products can often be tuned through variation of the metal catalyst.  
Such chemistry might therefore enable diverse chemical space to 
be explored, and the synthesis of bioactive chemotypes to be 
optimised. 
In this Concept, we describe the reported applications of ADS 
that have led to the discovery of bioactive small molecules.  We 
note the range of reaction classes and assay formats that have 
been used to underpin ADS.  In each case, it is explained how 
ADS was exploited to realise alternative medicinal chemistry 
strategies.  We discuss the value of the approach to allow diverse 
chemical space to be explored to yield distinctive starting points 
for molecular discovery.  Finally, we comment on the future 
challenges that would need to be addressed in order for ADS to 
become a mainstream lead generation approach. 
 




Figure 1. Overview of Activity-Directed Synthesis.  Designed reaction arrays harness combinations of alternative components (such substrates, co-substrates, 
catalysts and solvents).  The crude reaction products are directly screened for biological function, and the identified hit reactions inform the design of subsequent 
reaction arrays.  Finally, the most promising hit reactions are scaled up, and the products purified, structurally elucidated and characterised.
Discovery of androgen receptor modulators ligands based 
on novel scaffolds 
ADS was initially exploited in the discovery of androgen receptor 
(AR) modulators based on scaffolds with no previously annotated 
AR activity (Figure 2).[9]  AR is a nuclear receptor which acts as a 
transcription regulator, crucial for the expression and 
development of male sexual characteristics; mutations of the AR 
have been associated with prostate cancer and androgen 
sensitivity syndrome.[10] 
In round 1, twelve -diazo amides (A1-A12) were harnessed 
that each incorporated a fragment (4-cyano-3-trifluoromethyl-
phenyl) found in known AR ligands as well as a variable R’ group.  
It was envisaged that several different cyclisation pathways might 
be possible to yield products based on alternative scaffolds (Fig. 
2, Panel a).  In the reaction array, all combinations of the twelve 
substrates (A1-A12) and three dirhodium catalysts (1 mol%) were 
investigated in a single solvent (CH2Cl2) (Panel b, left).  The crude 
products were scavenged to remove metals, evaporated, and 
screened for agonism of the AR using a FRET-based assay (total 
product concentration: 10 M in 1% DMSO in pH 7.5 buffer).  Four 
substrates (A1, A3, A6, and A7), in combination with Rh2(OAc)4, 
resulted in product mixtures with significant activity, and these 
combinations informed the design of a second reaction array. 
 
In round 2, six diazo substrates were exploited: the four 
substrates identified in round 1, and two additional substrates 
(A11 and A12) that had not yielded bioactive products.  The six 
substrates were each treated with a metal catalyst (8 alternatives) 
in a specific solvent (4 alternatives).  The crude product mixtures 
were scavenged and evaporated as before, and screened at 10-
fold lower concentration (total product concentration: 1 M) (Fig. 
2, Panel b, middle).  It was observed that the most active product 
mixtures stemmed from two of the substrates (A1 and A3) in 
combination with dirhodium carboxylate catalysts. 
In round 3, the reaction array harnessed, in addition to A1 and 
A3, four additional structurally-related substrates (A1a-b and 
A3a-b).  The substrates were each treated with a dirhodium 
carboxylate catalyst (6 alternatives) in a specific solvent (3 
alternatives).  After screening at 10-fold lower concentration (total 
product concentration: 0.1 M) (Fig. 2, Panel b, right), the most 
promising reactions were scaled up, and the products purified and 
structurally elucidated (Fig. 2, Panel c).  All three products were 
found to be sub-micromolar modulators of AR: the agonists 1 and 
3 and the partial agonist 2.  Crucially, none of the ligands were 
based on scaffolds with any previously-annotated activity against 
AR. 
.




Figure 2. Activity-directed discovery of AR modulators based on scaffolds with no previously-annotated activity against AR.  Panel a: Potential cyclisation pathways 
of diazo substrates A1-A12.  Panel b: Activities of crude product mixtures formed in reaction arrays in rounds one (left), two (middle) and three (right), relative to 5 
M testosterone; hit reactions are highlighted (yellow box). Panel c: Reactions discovered that yield AR modulators.
Fragment-based discovery of androgen receptor agonists 
ADS was exploited to identify productive strategies for the 
growth of 4, a fragment that modulates AR (EC50 = 92 M) (Figure 
3, Panels a and b).[11]  Accordingly, four diazo substrates (B1-B4) 
were designed based on this fragment, with R’ groups selected to 
minimise the possibility of intramolecular reaction. 
In round 1, 192 of the 480 possible combinations of the 4 -
diazo substrates (B1-4), 9 co-substrates (C1-9) (plus no co-
substrate), 6 dirhodium catalysts and two solvents were explored.  
After screening the product mixtures at a total product 
concentration of 10 M, hit reactions were found that involved the 
diazo substrate B1 and either cyclohexene (C1) or indole (C2) 
(Panel c, left). 
In subsequent rounds, the co-substrates used were inspired by 
the productive co-substrates from the previous round, and 
screening was performed at increasing low total product 
concentration (Panel c, middle and right).  In round 2, reactions of 
the diazo substrate B1 with dihydropyran (C1a), 
dihydronaphthalene (C1b) or indene (C1c) were found to be 
productive; whilst, in round 3, reactions of B1 with the substituted 
dihydropyran C1a’ or the chromene C1b’ were identified. 
The hit reactions from all three rounds were scaled up, and the 
products purified, structurally elucidated and characterised.  It 
would found that the fragment 4 could be productively grown via 
cyclopropanation ( 5, round 1;  7, 8 or 9, round 2), C-H 
insertion into indole ( 6, round 1), O-H insertion ( 10, round 3) 
or reaction with a nitrile ( 11, round 3).  ADS had thus enabled 
fragment growth to afford four distinct chemotypes in parallel, and 
the yields of bioactive products were always good.  The activity of 
the fragment 4 had been improved ~125-fold in the case of the 
most active product 11 (EC50 = 730 nM).




Figure 3. Activity-directed discovery of AR modulators by fragment growth. Panel a: Structure of a fragment that binds to AR. Panel b: Potential intermolecular 
reactions of the diazo substrates B1-4. Panel c: Evolution of teh structure of AR modulators through three rounds of ADS.   
Expansion of a series of antibacterials 
ADS enabled expansion[12] of a series[13] of antibacterial 
quinazolinones.  Pd-catalysed cascade chemistry was chosen to 
drive ADS due to its potential to yield products based on many 
possible scaffolds (including quinazolinones) (Figure 4, Panel a).  
Here, the alternative products stem from the possibility of cross-
coupling with or without carbonylation, and with or without 
subsequent cyclisation. 
A reaction array of 220 reactions was executed based on all 
combinations of ten substrates (D1-D10) (plus no substrate) and 
nineteen co-substrates (E1-E19) (plus no co-substrate) (see 
Figure 4, Panel c for conditions).  The components were chosen 
to offer the possibility that multiple products might be formed, and 
to explore a diverse range of substitution patterns.  After 48 h, the 
reactions mixtures were filtered through silica, evaporated, and 
screened against S. aureus ATCC29213 at a total product 
concentration of 50 μM (Figure 4, Panel b). 
The products of six reactions displayed antibacterial activity 
against both replicate cultures: substrate D1 with co-substrates 
E1 or E18; substrate D7 with co-substrate E18; and substrate D10 
with co-substrates E1, E6 or E18.  The combination of D1 and E1 
had previously been validated during the establishment of the 
ADS protocols, and therefore the remaining five reactions were 
scaled up and the products isolated, structurally elucidated and 
characterised.  In each case, quinazolinones products were 
identified (e.g. 12-15) which had minimum inhibitory 
concentrations (MIC) ranging from 0.016-1 g/mL (Figure 4, 
Panels c and d). The study demonstrated that ADS could enable 
efficient expansion of the SAR of a series of antibacterials and 
enabled key features for antibacterial activity to be identified. At 
the 2-position of the quinazolinone, a two-atom linker to a 
hydrophobic substituent was essential and conformational 
restriction could be tolerated. At the 3-position of the 
quinazolinone, a phenyl ring bearing a meta hydrogen donor 
substituent was required. The study additionally demonstrated the 
feasibility of ADS with a phenotypic assay and alternative 
underpinning chemistry. 




Figure 4. Activity-directed expansion of a series of antibacterial quinazolinones. 
Panel a: Potential Pd-catalysed reaction pathways. Panel b: Growth inhibition 
of crude product mixtures formed in the reaction array; hit reactions are 
highlighted (yellow box). Panel c: Reaction that yielded the antibacterial 
quinazolinone 12. Panel d: Some other antibacterial quinazolinones that were 
identified following scale up. 
Discovery of novel inhibitors of the p53/hDM2 protein-protein 
interaction by scaffold hopping 
ADS facilitated the discovery of new scaffolds which enable the 
hot spot residues of a protein-protein interaction (PPI) to be 
targeted.[14] It was shown that metal carbenoid chemistry could 
link fragments containing substituents that mimic hot spot 
residues of the p53 peptide to yield novel p53/hDM2 inhibitors.  
An initial array of 154 reactions was performed using seven 
diazo substrates (F1-F7), ten co-substrates (G1-G10) (plus no co-
substrate) and two dirhodium catalysts. The diazo substrates and 
co-substrates were designed to include substituents, such as 
phenyl, chlorophenyl and branched/cyclic/fluorinated alkyl groups, 
that may mimic hot spot residues of p53 peptide. Many of these 
groups are found in known p53/hDM2 inhibitors. 
After 24 h, the reactions were scavenged, evaporated, 
dissolved in DMSO and screened in duplicate at a total product 
concentration of 20 M using an established fluorescence 
anisotropy (FA) assay (Figure 5, Panel a, left). Significant 
bioactivity was identified in the products of reactions with the 
diazo substrates F2, F3 and F4.  In the case of F3, activity was 
observed for reactions with or without a co-substrate, suggesting 
that F3 alone may yield bioactive product(s); the Rh2piv4-
catalysed reaction of F3 was shown to yield both 16 and 17 
(Figure 5, Panel b, left).  LC/MS of three hit reactions involving F2 
and F4 confirmed the formation of intermolecular reaction 
products in each case. 
The intermolecular hit reactions from round 1 informed the 
design of a second array of 196 reactions.  The array exploited 
six diazo substrates (including the new substrates F3a, F2a and 
F7a), 16 co-substrates (including 11 new co-substrates) and the 
same two dirhodium catalysts. After screening, six additional hit 
reactions were identified (Figure 5, Panel a, right). 
Reactions with significant bioactivity from both rounds were 
scaled up 50-fold, and the products purified and structurally 
elucidated. Products were identified from a range of reaction 
types (Figure 5, Panel b): intramolecular insertion into an aryl C-
H bond (16); insertion into an O-H bond (18); 
cyclopropanation (19); and insertion into an indoyl C-H bond 
(e.g. 20). The activity of the purified products was evaluated in 
the fluorescence anisotropy assay and were further validated as 
hDM2 binders by 1H-15N HSQC NMR spectroscopy.   
The use of metal carbenoid chemistry to link substrates 
containing substituents with the potential to mimic p53 hot spot 
residues enabled four distinct and novel series of p53/hdm2 
inhibitors to be discovered in parallel. It was concluded that 17, 
18, 19 and 20 all contain pairs of substituents that target two hot 
spots.  These ligands are highly dissimilar to each other, and to 
all ligands in ChEMBL with annotated activity against hDM2.  Here, 
ADS enabled experimental scaffold-hopping, resulting in the 
discovery of ligands in which common fragments were displayed 
in the context of alternative scaffolds.  PPIs generally do not have 
defined small-molecule binding sites, yet ADS was shown to 
identify distinctive starting points for the discovery of PPI inhibitors. 
  
 




Figure 5. Activity-directed discovery of p53/hDM2 PPI inhibitors.  Panel a: Activities of crude product mixtures formed in reaction arrays in rounds one (left) and 
round two (right); hit reactions are highlighted (yellow box). Panel b: Reactions discovered that yield p53/hDM2 PPI inhibitors. 
Table 1. Summary of activity-directed synthesis case studies 






Number of rounds and 
reactions 
Discoveries 
1 (Figure 2[9]) Androgen receptor 
(FRET) 
Metal carbenoid Scaffold discovery 3 rounds (36, 192 and 
108 reactions) 
Agonists and partial agonists with 
sub-micromolar activity 
Scaffolds with no previously-
annotated AR activity 
2 (Figure 3[11]) Androgen receptor 
(FRET) 
Metal carbenoid Fragment growth 3 rounds (192, 86 and 48 
reactions) 
Four distinct chemotypes 
Elaborated fragments with low 
micromolar (or better) activity 





SAR expansion 1 round (220 reactions) Expanded series of antibacterial 
quinazolinones 
4 (Figure 5[14]) p53/hDM2 PPI 
(fluorescence 
anisotropy) 
Metal carbenoid Scaffold hopping 2 rounds (154 and 192 
reactions) 
Experimental scaffold hopping to 
yield low micromolar PPI inhibitors  
Ligands for a binding site not 
evolved to bind small molecules 
Discussion   
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The above case studies showcase ADS as an efficient 
approach for the discovery of novel bioactive small molecules.  
ADS requires a robust high-throughput assay, and both target-
oriented and phenotypic assays have been shown to be suitable 
(Table 1).  Although over 200 reactions were conducted in each 
case, only a few reactions (typically less than 10) needed to be 
scaled up and the products purified and structurally elucidated.  
ADS thus focuses resources on reactions that yield bioactive 
products. 
Retrospective analyses have provided insights into the 
mechanism of evolution of activity-directed syntheses.  The yield 
of the most active component may be optimised in an ADS 
workflow: for example, the yield of the AR partial agonist 3 
increased significantly when a new catalyst was introduced.[9]  
The focus on reactions which result in optimised yields of 
bioactive products (such as the elaborated AR agonists[11] in 
Figure 3) can greatly facilitate subsequent purification.  However, 
optimisation of the structure of a bioactive product is also 
possible: this can simply expand a series of ligands (e.g. AR 
agonists[11] 7-9, Figure 3 and antibacterial quinazolinones[12] 
Figure 4), or it can lead to entirely new chemotypes (such as the 
AR agonists[11] 10-11 and the PPI inhibitors[14] 19-20). 
The use of a promiscuous, yet tunable, reaction toolkit allows 
multiple diverse, yet synthetically-accessible, chemotypes to be 
explored in parallel.  This contrasts with overwhelming medicinal 
chemistry practice in which perceived synthetic accessibility tends 
to influence which molecules are prioritised for synthesis.  In 
several cases, retrospective analysis showed that other 
chemotypes had been explored in ADS reaction arrays: for 
example, intramolecular insertion into an aryl C-H bond in 
substrates similar to A3 gave oxindoles rather than lactams as 
products.[9]  These alternative chemotypes were not taken forward 
because other reactions had resulted in more active product 
mixtures. 
ADS has enabled a range of medicinal chemistry strategies to 
be realised.  It has enabled the discovery of ligands based on 
more constrained scaffolds (such as the AR modulators 1-3[9]); 
productive fragment growth (e.g. to give the AR agonists 
compounds 5-11[11]); expansion of compound series (e.g. the 
antibacterials 12-15[12]); and scaffold hopping (e.g. to give the 
p53/hDM2 inhibitors 17-20[14]). In each case, ADS enabled the 




ADS has the potential to become a mainstream lead discovery 
approach. It is highly general, requiring only access to a suitably 
robust high-throughput assay.  To date, substrate design has 
been informed by known ligands, for example by deconstruction 
of known inhibitors or harnessing the structures of fragment hits. 
However, exploiting larger, target-agnostic reaction arrays, it may 
also be possible to discover wholly novel chemotypes.  To 
manage the size of initial reaction arrays based on each reaction, 
whilst enabling diverse chemical space to be explored, we 
envisage that selected combinations of fragment-sized substrates 
(perhaps chosen from <100 diverse alternatives) might be 
explored. 
It may also be possible to harness late-stage functionalisations 
to enable activity-directed tuning of the potency, selectivity and/or 
molecular properties of ligands; recent advances in photoredox 
catalysis[15] and C-H functionalisation[16] chemistry may prove 
crucial for realising this goal.  Additionally, we note the potential 
of other ligand-directed synthetic approaches (in addition to those 
outlined in this Concept article) to explore in parallel small 
molecules based on multiple scaffolds.[17] 
Finally, we believe that ADS has the potential to enable the 
autonomous discovery of bioactive small molecules.  All stages of 
the workflow are performed in parallel and are amenable to 
integration and automation.  Although human-driven to date, it 
may be possible to develop algorithms to design reaction arrays 
that enable diverse, yet relevant, chemical space to be explored. 
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Activity-directed synthesis has driven the parallel discovery of diverse bioactive small molecules for a range of targets.  The approach 
has enabled a range of medicinal chemistry strategies to be realised including scaffold constraint; fragment-based discovery; expansion 
of a series of ligands; and scaffold hopping.  Future scientific challenges, and the prospects of activity-directed synthesis becoming a 
mainstream lead generation approach, are discussed.  
Institute and/or researcher Twitter usernames: @Adam_S_Nelson  @AstburyCentre  @RosFrankInst 
